PGEN: Precigen Inc

PGEN新闻

• 20:30 The "Calendar Trick" for Huge Biotech Gains - And 3 Stocks I'm Watching
• 12:02 Constellation Brands, Caribou Biosciences And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
• 15:21 Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
• 14:46 Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
• 14:44 PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
• 14:36 Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
• 12:29 The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
• 11:09 Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
• 10:57 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
• 15:16 UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
• 07:35 Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
• 17:34 NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
• 16:47 uniQure Plunges on Additional Data From Huntington's Disease Study
• 16:31 Precigen: FDA’s Platform Technology Designation And Institutional Crossover Effect (PGEN)
• 15:08 PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
• 13:22 IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
• 13:11 Here's Why You Should Add URGN Stock to Your Portfolio Now
• 15:37 AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
• 14:13 KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
• 14:12 Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
• 13:20 Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
• 13:17 KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
• 13:06 Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
• 15:04 FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication